Crossmark

A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

Crossref DOI link: https://doi.org/10.1007/s10147-015-0895-3

Published Online: 2015-09-04

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Ogata, Yutaka

Shimokawa, Mototsugu

Tanaka, Takaho

Emi, Yasunori

Oki, Eiji

Saeki, Hiroshi

Sadanaga, Noriaki

Kusumoto, Tetsuya

Touyama, Tetsuo

Kimura, Masami

Baba, Hideo

Akagi, Yoshito

Shirouzu, Kazuo

Maehara, Yoshihiko
License Information

License valid from 2015-09-04